Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 3, 2016, Pages 327-344

  Paul, Laure Peyro Saint ^a   Debruyne, Danièle ^a   Bernard, Delphine ^b   Mock, Donald M ^c   Defer, Gilles L ^a,d  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d GIP CYCERON   (France)

Author keywords

Biotin; energy metabolism; pharmacodynamics; pharmacokinetics; progressive multiple sclerosis; remyelination

Indexed keywords

BIOTIN; MD 1003; PLACEBO; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENERGY YIELD; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PERICARDIAL EFFUSION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TERATOGENICITY; URINARY EXCRETION; ANIMAL; BIOAVAILABILITY; DOSE RESPONSE; PATHOPHYSIOLOGY;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 84959131013     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1136288     Document Type: Review

References (114)

1. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis (EMA/CHMP/771815/2011, Rev. 2). Adopted Guideline. 2015; 1-20.
2. Multiple Sclerosis International Federation (MSIF). Atlas of MS 2013. Mapping multiple sclerosis around the world; 2013.
3. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain: J Neurol. 2006; 129 (Pt 3): 606-616.
4. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83 (3): 278-286.
5. Matthews B. Symptoms and signs of multiple sclerosis. In: Alastair Compston GE, Lassmann H, McDonald I, et al., ed. McAlpines multiple sclerosis. 3rd ed. London: Churchill Livingstone; 1998. p. 145-190.
6. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000; 343 (13): 938-952.
7. Stys PK, Zamponi GW, Van Minnen J, et al. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012; 13 (7): 507-514.
8. Lassmann H, Van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012; 8 (11): 647-656.
9. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis. 2013; 19 (6): 765-774.
10. Edan G, Kappos L, Montalban X, et al. Long-Term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014; 85 (11): 1183-1189.
11. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology. 2004; 62 (4): 601-606.
12. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010; 81 (8): 907-912.
13. Zhang T, Shirani A, Zhao Y, et al. Beta-interferon exposure and onset of secondary progressive multiple sclerosis. Eur J Neurol. 2015; 22 (6): 990-1000.
14. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: Prospects and promise. Ann Neurol. 2013; 74 (3): 317-327.
15. National Institute of Health and Care Excellence (NICE). Management of multiple sclerosis in primary and secondary care. NICE Clinical Guideline 2014;186:36.
16. Haute Autorité de la Santé (HAS). Sclérose en plaques. Guide-Affection de Longue Durée (ALD). France: Saint-Denis La Plaine; 2006.
17. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet. 1988; 2 (8604): 179-183.
18. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990; 27 (6): 591-605.
19. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet. 1991; 337 (8739): 441-446.
20. Noseworthy JH, OBrien P, Erickson BJ, et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology. 1998; 51 (5): 1342-1352.
21. Kappos L. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998; 352 (9139): 1491-1497.
22. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology. 2000; 54 (9): 1726-1733.
23. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000; 54 (5): 1145-1155.
24. SPECTRIMS SPECToRI-B-AiMSG. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology. 2001; 56 (11): 1496-1504.
25. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002; 59 (5): 679-687.
26. Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet. 2002; 360 (9350): 2018-2025.
27. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004; 75 (5): 706-710.
28. Panitch H, Miller A, Paty D, et al. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004; 63 (10): 1788-1795.
29. Hommes OR, Sørensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004; 364 (9440): 1149-1156.
30. Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Multiple Sclerosis. 2007; 13 (9): 1107-1117.
31. Wolinsky JS, Narayana PA, OConnor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007; 61 (1): 14-24.
32. Hawker K, OConnor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66 (4): 460-471.
33. Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011; 77 (16): 1551-1560.
34. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12 (9): 857-865.
35. Novartis. Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS). Press release. Basel. 2014;4.
36. MedDay Pharmaceuticals. MedDay reports positive pivotal Phase III study results with MD1003 in patients with progressive multiple sclerosis. Press release. Paris. 2015.
37. F. Hoffmann-La Roche Ltd. Roches ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis. Press release. Basel, 2015.
38. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015; 14 (2): 208-223.
39. Hauser SL. Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed. Jama. 2015; 313 (3): 251-252.
40. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009; 373 (9665): 732-738.
41. Jepson S, Vought B, Gross CH, et al. LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem. 2012; 287 (26): 22184-22195.
42. Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014; 1 (2): e18.
43. Cadavid D, Balcer L, Galetta S, et al. Efficacy analysis of the anti-LINGO-1 monoclonal antibody BIIB033 in acute optic neuritis: the RENEW Trial (P7.202). Neurology. 2015; 84:(14 Supplement).
44. Cadavid D, Klistorner A, Chai Y, et al. Evidence that the anti-LINGO-1 monoclonal antibody BIIB033 protects against multifocal visual evoked potential amplitude loss in the fellow eye of subjects with unilateral acute optic neuritis. ECTRIMS; 2015. Barcelona (Spain); 2015;23(S11):780-808.
45. Mitsunaga Y, Ciric B, Van Keulen V, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. Faseb J. 2002; 16 (10): 1325-1327.
46. Warrington AE, Bieber AJ, Ciric B, et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res. 2007; 85 (5): 967-976.
47. Mock DM. Biotin. In: Coates PM, Betz JM, Blackman MR, et al. editors. Encyclopedia of dietary supplements. 2nd edn. London: Informa UK Ltd: 2010.
48. Mock DM. Biotin. In: Zempleni J, Suttie JW, Gregory JF, et al., editors. Handbook of vitamins. 5th edn. Boca Raton (FL): CRC Press; 2013. p. 397-420.
49. Said HM. Biotin: biochemical, physiological and clinical aspects. Subcell Biochem. 2012; 56: 1-19.
50. Institute of Medicine (IOM). Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vVitamin B12, pantothenic acid, biotin, and choline. Washington (DC): The National Academies Press; 1998.
51. Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011; 104 (1-2): 27-34.
52. Mardach R, Zempleni J, Wolf B, et al. Biotin dependency due to a defect in biotin transport. J Clin Invest. 2002; 109 (12): 1617-1623.
53. Agence Nationale de Sécurité du Médicament (ANSM). BIOTINE BAYER 5 mg, comprimé. Rcp. 2014;R0246838:3.
54. Wolf B. Clinical issues and frequent questions about biotinidase deficiency. Mol Genet Metab. 2010; 100 (1): 6-13.
55. Ozand PT, Gascon GG, Al Essa M, et al. Biotin-responsive basal ganglia disease: a novel entity. Brain: J Neurol. 1998; 121 (Pt 7): 1267-1279.
56. Zeng WQ, Al-Yamani E, Acierno JS Jr., et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet. 2005; 77 (1): 16-26.
57. Subramanian VS, Marchant JS, Said HM. Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2. Am J Physiol Cell Physiol. 2006; 291 (5): C851-9.
58. Debs R, Depienne C, Rastetter A, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol. 2010; 67 (1): 126-130.
59. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain: J Neurol. 2009; 132 (Pt 5): 1161-1174.
60. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015; 14 (2): 183-193.
61. Mock DM. Biotin. In: Ziegler EEFJL., editors. Present knowledge in nutrition. 7 th edn. Washington (DC): International Life Sciences Institutes-Nutrition Foundation; 1996. p. 220-235.
62. Cowan FM, Klein DL, Armstrong GR, et al. Augmentation and inhibition of delayed hypersensitivity by Staphylococcus aureus protein A. Biomedicine. 1979; 30 (5): 241-244.
63. Wiedmann S, Eudy JD, Zempleni J. Biotin supplementation increases expression of genes encoding interferon-gamma, interleukin-1beta, and 3-methylcrotonyl-CoA carboxylase, and decreases expression of the gene encoding interleukin-4 in human peripheral blood mononuclear cells. J Nutr. 2003; 133 (3): 716-719.
64. Zempleni J, Helm RM, Mock DM. In vivo biotin supplementation at a pharmacologic dose decreases proliferation rates of human peripheral blood mononuclear cells and cytokine release. J Nutr. 2001; 131 (5): 1479-1484.
65. Okabe N, Urabe K, Fujita K, et al. Biotin effects in Crohns disease. Dig Dis Sci. 1988; 33 (11): 1495-1496.
66. Baez-Saldana A, Diaz G, Espinoza B, et al. Biotin deficiency induces changes in subpopulations of spleen lymphocytes in mice. Am J Clin Nutr. 1998; 67 (3): 431-437.
67. Kumar M, Axelrod AE. Cellular antibody synthesis in thiamin, riboflavin, biotin and folic acid-deficient rats. Proc Soc Exp Biol Med. 1978; 157 (3): 421-423.
68. Kung JT, Mackenzie CG, Talmage DW. The requirement for biotin and fatty acids in the cytotoxic T-cell response. Cell Immunol. 1979; 48 (1): 100-110.
69. Pruzansky J, Axelrod AE. Effect of B-complex deficiencies on rat serum complement. Proc Soc Exp Biol Med. 1955; 88 (2): 179-181.
70. Rabin BS. Inhibition of experimentally induced autoimmunity in rats by biotin deficiency. J Nutr. 1983; 113 (11): 2316-2322.
71. Helm RM, Mock NI, Simpson P, et al. Certain immune markers are not good indicators of mild to moderate biotin deficiency in rats. J Nutr. 2001; 131 (12): 3231-3236.
72. Sedel F, Bernard D, Mock DM, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. Forthcoming 2015.
73. Kim KH. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu Rev Nutr. 1997; 17: 77-99.
74. Frigg M, Straub OC, Hartmann D. The bioavailability of supplemental biotin in cattle. Int J Vitam Nutr Res. 1993; 63 (2): 122-128.
75. Sawamura H, Fukuwatari T, Shibata K. Effects of excess biotin administration on the growth and urinary excretion of water-soluble vitamins in young rats. Biosci Biotechnol Biochem. 2007; 71 (12): 2977-2984.
76. Zempleni J, Mock DM. Bioavailability of biotin given orally to humans in pharmacologic doses. Am J Clin Nutr. 1999; 69 (3): 504-508.
77. Wang KS, Kearns GL, Mock DM. The clearance and metabolism of biotin administered intravenously to pigs in tracer and physiologic amounts is much more rapid than previously appreciated. J Nutr. 2001; 131 (4): 1271-1278.
78. Informatics Inc. Scientific literature reviews on generally recognized as safe (GRAS) food ingredients-Biotin. Technical Report; 1974.
79. Mock DM, Malik MI. Distribution of biotin in human plasma: most of the biotin is not bound to protein. Am J Clin Nutr. 1992; 56 (2): 427-432.
80. Spector R, Johanson CE. Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J Neurochem. 2007; 103 (2): 425-438.
81. Uchida Y, Ito K, Ohtsuki S, et al. Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells. J Neurochem. 2015; 134 (1): 97-112.
82. Park S, Sinko PJ. The blood-brain barrier sodium-dependent multivitamin transporter: a molecular functional in vitro-in situ correlation. Drug Metab Dispos. 2005; 33 (10): 1547-1554.
83. Spector R, Mock DM. Biotin transport and metabolism in the central nervous system. Neurochem Res. 1988; 13 (3): 213-219.
84. Wang KS, Patel A, Mock DM. The metabolite profile of radioisotope-labeled biotin in rats indicates that rat biotin metabolism is similar to that in humans. J Nutr. 1996; 126 (7): 1852-1857.
85. Expert Group on Vitamins and Minerals (EGVM). Safe upper levels for vitamins and minerals. London: Food Standards Agency; 2003.
86. Rodriguez-Melendez R, Griffin JB, Zempleni J. The expression of genes encoding ribosomal subunits and eukaryotic translation initiation factor 5A depends on biotin and bisnorbiotin in HepG2 cells. J Nutr Biochem. 2006; 17 (1): 23-30.
87. Zempleni J, Green GM, Spannagel AW, et al. Biliary excretion of biotin and biotin metabolites is quantitatively minor in rats and pigs. J Nutr. 1997; 127 (8): 1496-1500.
88. Bitsch R, Salz I, Hotzel D. Studies on bioavailability of oral biotin doses for humans. Int J Vitam Nutr Res. 1989; 59 (1): 65-71.
89. Duchossoy Y, Bellamy F. MD1003 (biotin): Investigators Brochure Edition 5. MedDay Pharmaceuticals; 2015.
90. Mock DM, Mock NI. Serum concentrations of bisnorbiotin and biotin sulfoxide increase during both acute and chronic biotin supplementation. J Lab Clin Med. 1997; 129 (3): 384-388.
91. Tabarki B, Al-Shafi S, Al-Shahwan S, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology. 2013; 80 (3): 261-267.
92. Newman NJ, Biousse V. Hereditary optic neuropathies. Eye (Lond). 2004; 18 (11): 1144-1160.
93. Sedel F, Challe G, Vignal C, et al. Biotin sensitive leukodystrophy. J Inherit Metab Dis. 2011; 2011: S267.
94. Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015; 4 (2): 159-169.
95. MedDay Pharmaceuticals. MedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with progressive multiple sclerosis. Press release. Paris. 2015.
96. MedDay Pharmaceuticals. MedDay provides update on MS-ON study of MD1003. Press release. Paris. 2015.
97. Fiume MZ, On behalf of the Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of biotin. Int J Toxicol. 2001;20(suppl 4): 1-12.
98. Crittenden PJ. Studies on the pharmacology of biotin. Arch Int Pharmacodyn Ther. 1948; 76 (4): 417-423.
99. Paul PK, Duttagupta PN. The effect of an acute dose of biotin at the pre-implantation stage and its relation with female sex steroids in the rat. J Nutr Sci Vitaminol (Tokyo). 1975; 21 (2): 89-101.
100. Paul PK, Duttagupta PN. The effect of an acute dose of biotin at a post-implantation stage and its relation with female sex steroids in the rat. J Nutr Sci Vitaminol (Tokyo). 1976; 22 (3): 181-186.
101. Sawamura H, Ikeda C, Shimada R, et al. Dietary intake of high-dose biotin inhibits spermatogenesis in young rats. Congenit Anom (Kyoto). 2015; 55 (1): 31-36.
102. Messaritakis J, Kattamis C, Karabula C, et al. Generalized seborrhoeic dermatitis. Clinical and therapeutic data of 25 patients. Arch Dis Child. 1975; 50 (11): 871-874.
103. Michalski AJ, Berry GT, Segal S. Holocarboxylase synthetase deficiency: 9-year follow-up of a patient on chronic biotin therapy and a review of the literature. J Inherit Metab Dis. 1989; 12 (3): 312-316.
104. Koutsikos D, Fourtounas C, Kapetanaki A, et al. Oral glucose tolerance test after high-dose i.v. biotin administration in normoglucemic hemodialysis patients. Ren Fail. 1996; 18 (1): 131-137.
105. Santer R, Muhle H, Suormala T, et al. Partial response to biotin therapy in a patient with holocarboxylase synthetase deficiency: clinical, biochemical, and molecular genetic aspects. Mol Genet Metab. 2003; 79 (3): 160-166.
106. Adhisivam B, Mahto D, Mahadevan S. Biotin responsive limb weakness. Indian Pediatr. 2007; 44 (3): 228-230.
107. Dabbagh O, Brismar J, Gascon GG, et al. The clinical spectrum of biotin-Treatable encephalopathies in Saudi Arabia. Brain Dev. 1994; 16 (Suppl): 72-80.
108. Straussberg R, Shorer Z, Weitz R, et al. Familial infantile bilateral striatal necrosis: clinical features and response to biotin treatment. Neurology. 2002; 59 (7): 983-989.
109. Yamada K, Miura K, Hara K, et al. A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations. BMC Med Genet. 2010; 11: 171.
110. El-Hajj TI, Karam PE, Mikati MA. Biotin-responsive basal ganglia disease: case report and review of the literature. Neuropediatrics. 2008; 39 (5): 268-271.
111. Debourdeau PM, Djezzar S, Estival JL, et al. Life-Threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H. Ann Pharmacother. 2001; 35 (4): 424-426.
112. Kwok JS, Chan IH, Chan MH. Biotin interference on TSH and free thyroid hormone measurement. Pathology. 2012; 44 (3): 278-280.
113. Wijeratne NG, Doery JC, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology. 2012; 44 (7): 674-675.
114. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004; 63 (10): 1779-1787.